Home  /  Resource Library  /  Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin

Result of a phase II study of MOR208 for relapsed B-cell lymphomas.